Omrix Biopharmaceuticals OMRI
-
Omrix to Be Acquired by J&J
Omrix Biopharmaceuticals OMRI announced Monday that it will be acquired by Johnson & Johnson JNJ in a cash tender offer of $438 million, or $25 per share …
-
Omrix 3Q Meets Expectations
Omrix Biopharmaceuticals OMRI reported third-quarter earnings today, and because the firm remains on track to meet our expectations for the year, we are …
-
Omrix Product Sees Red Flag
Omrix Biopharmaceuticals OMRI announced Thursday that it has suspended a Phase II trial testing its Fibrin Pad to treat patients with mild to moderate bleeding …
-
Omrix Posts Promising 2Q
Despite the promising revenue growth Omrix Biopharmaceuticals OMRI reported for its second quarter, we are maintaining our fair value estimate. Total revenue reached $19.2 million, a 71 …
-
Omrix Pipeline Pushing Forward
Omrix Biopharmaceuticals OMRI expects to make significant progress with clinical trials during the remainder of 2008, and we're keeping a close eye on the …
-
Omrix Disappoints in 4Q
Omrix Biopharmaceuticals OMRI announced its full-year financial results Thursday, and while it had released limited financials for 2007 at the beginning of …
-
Omrix under Review
We're putting Omrix Biopharmaceuticals OMRI under review as we investigate the stock's unusually high trading volume and price decline Feb. 1. Although competitive pressures …
-
ZymoGenetics Awaits Key Approval
… already developing strategies to convert the biggest purchasers of thrombin to rThrombin. Despite competition from Omrix's OMRI human thrombin Evithrom--which received FDA approval in late August--we see U.S. sales of rThrombin surpassing $200 …
-
Omrix Rebounds in Q3
Omrix OMRI recovered nicely in the third quarter, reporting almost $16 million in total revenue as its fibrin sealant Evicel benefited from …
-
ZymoGenetics Sees Delay
… on our fair value estimate. We still believe rThrombin has several advantages over a similar product from Omrix Biopharmaceuticals OMRI , which is expected to gain FDA approval shortly, and we still model a 90% probability that rThrombin will …